A bioresorbable subdermal implant for sustained delivery of a novel maturation inhibitor to prevent HIV infection

Ended Project Grant Awarded Last action

Award ID
R01AI154561
Recipient
Awarding agency
Obligated
$8,022,598

Award facts

Assistance listing
93.855 Allergy and Infectious Diseases Research
Completion date
Originally
Funding
  • $7,145,241.00 Federal
  • $877,357.00 Non-federal
Place of performance
California, USA

Award details come from USAspending.gov.

Transactions

Action Federal Non-federal Date
Amendment $0 $0
Amendment $886,859 $0
Amendment $890,560 $0
Amendment $890,560 $0
Amendment $904,172 $0
Amendment $904,172 $0
Amendment $877,357 $0
Amendment $877,357 $877,357
Original award $914,204 $0

Subawards

Subrecipient Amount Awarded
Vanderbilt University Assess the in vivo distribution of small molecule antiretroviral compounds in animal tissue. $129,842
University Of Texas Medical Branch At Galveston Perform studies in sheep for assessment of pharmacokinetics and safety of subcutaneous implants releasing anti-retrovirals for the prevention of HIV. $250,497
DFH Pharma, Inc. Manufacture and delivery of investigational HIV maturation inhibitor compounds. $183,000

Quick answers

Who received award R01AI154561?

R01AI154561 was awarded to Oak Crest Institute Of Science by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on August 28, 2020.

How much is award R01AI154561 worth?

$8,022,598 has been obligated on R01AI154561: $7,145,241 in federal funding and $877,357 in non-federal funding.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login